Synopsis

A fresh wave of anti-obesity medications are generating considerable excitement, promising a significant shift for both the National Health Service and countless patients. Treatments often referred to as 'skinny jabs,' exemplified by Wegovy, have previously been largely accessible only to high-profile individuals and those able to afford private prescriptions. Now, the NHS is beginning to make these medications available. Will they deliver on their considerable promise? How widely will they be a